Page 16 - Read Online

Gabriele et al. J Cancer Metastasis Treat 2018;4:17 I http://dx.doi.org/10.20517/2394-4722.2018.06 Page 11 of 17

Patient consent
Not applicable.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on
premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol
Nutr Food Res 2009;53:171-84.
3. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F; European Association of Urology. EAU
Guidelines on prostate cancer. Eur Urol 2005;48:546-51.
4. Borley N, Feneley MR. Prostate cancer: diagnosis and staging. Asian J Androl 2009;11:74-80.
5. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337-47.
6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental
and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med
2000;343:78-85.
7. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer
associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
8. Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ 1998;159:807-13.
9. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J,
Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL,
O’Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL;
UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons’ Section of Oncology; UK ProtecT Study
Collaborators; Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C,
Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility.
Nat Genet 2008;40:316-21.
10. Li Q, Gu C, Zhu Y, Wang M, Yang Y, Wang J, Jin L, Zhu ML, Shi TY, He J, Zhou X, Ye DW, Wei Q. Polymorphisms in the mTOR gene
and risk of sporadic prostate cancer in an Eastern Chinese population. PLoS One 2013;8:e71968.
11. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade
prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007;31:1246-55.
12. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003;8:29-37.
13. Chakravarthi S, Yang DLW, Thanikachalam P, Nagaraja HS, Bukhari NI. Assessment of proliferative index and its association with Ki-
67 antigen molecule expression in nodular hyperplasia of prostate. Indian J Sci Technol 2009;2:1-4.
14. Ramsay AK, McCracken SR, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK,
Seywright M, Marquez R, Keller E, Leung HY. ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer
2011;104:664-72.
15. Ling Z, Liu D, Zhang G, Liang Q, Xiang P, Xu Y, Han C, Tao T. miR-361-5p modulates metabolism and autophagy via the Sp1-
mediated regulation of PKM2 in prostate cancer. Onco Rep 2017;38:1621-8.
16. Wang R, Xu J, Saramäki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson
PS, Marshall FF, Zhau HE, Chung LW. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in
chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004;64:1589-94.
17. Garber K. Energy deregulation: licensing tumors to grow. Science 2006;312:1158-9.
18. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-4.
19. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic
carcinoma. Cancer Res 1983;43:1809-18.
21. Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol 1999;180:431-8.
22. Kaini RR, Sillerud LO, Zhaorigetu S, Hu CA. Autophagy regulates lipopysis and cell survival though lipid droplet degradation in
androgen-sensitive prostate cance cells. Prostate 2012;72:1412-22.
23. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, May M, Bray K, Mathew R, Beaudoin B, Karp C, Stein M, Foran DJ,
White E. Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate
2008;68:1743-52.